Afoxolaner

* Afoxolaner * Isoxazoline ectoparasiticide

* N-[2-oxo-2-[(2,2,2-trifluoro-1-(trifluoromethyl)ethyl]amino]-4-(trifluoromethyl)phenyl]-4-[5-(3,5-dichlorophenyl)-4,5-dihydroisoxazol-3-yl]benzamide

* NexGard

Appearance: White to off-white crystalline powder

Assay (HPLC): ≥ 98%

Identification: IR/UV spectrum complies

Melting Point: ~ 100–105 °C

Loss on Drying: ≤ 0.5%

Residual Solvents: Within ICH limits

Heavy Metals: ≤ 10 ppm

Mode of Action: Afoxolaner belongs to the isoxazoline class and acts as a potent antagonist of ligand-gated chloride channels (GABA- and glutamate-gated channels) in insects and acarines, leading to uncontrolled nervous activity and parasite death.  

Spectrum: Broad ectoparasiticide activity. Effective against fleas (Ctenocephalides felis) and multiple tick species (Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Amblyomma americanum).  

Additional Effects: Begins killing fleas within 4 hours and maintains efficacy for up to 1 month. Breaks flea life cycle by killing before egg laying.  

Key Features: Oral systemic insecticide and acaricide for veterinary use (mainly dogs). Convenient monthly chewable formulation. Long-lasting efficacy and rapid onset of action.  

In short: Afoxolaner is an oral isoxazoline ectoparasiticide with rapid and persistent efficacy against fleas and ticks, widely used in veterinary medicine.